FDA Moves To Require Premarket Approval For Vaginal Mesh
Law360, New York (April 29, 2014, 12:56 PM EDT) -- The U.S. Food and Drug Administration on Tuesday issued two proposed orders that would reclassify surgical mesh for transvaginal repair of pelvic organ prolapse as a high-risk device and would require manufacturers to apply for premarket approval with the agency.
The two orders would address the health risks associated with the mesh, which is used to treat women whose internal structures become so weak or broken that their organs drop from their normal position and bulge into the vagina. Currently, the surgical mesh is classified as a moderate-risk device, according to the agency.
"The FDA has identified clear risks associated with...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!